drugset / Trial / NCT03274882
Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of S 95005 in patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to standard chemotherapies in terms of Progression-Free Survival rate at 2 months in the Russian population.
Timeline
- Start
- 2017-03-03
- Primary completion
- 2017-12-31
- Completion
- 2018-12-03
Publications
- Background Fedyanin M, Chekini D, Chubenko V, Tjulandin S, Zhabina A, Amellal N, Aubel P, Gandossi E, Moiseenko V. Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis. Ann Oncol. 2019 Jul;30(Supplement 4):IV16. doi: 10.1093/annonc/mdz155.057
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tipiracil | Small molecule | 7.065 mg | Oral |
| Subject | Tipiracil | Small molecule | 9.42 mg | Oral |
| Subject | Trifluridine | Small molecule | 15 mg | Oral |
| Subject | Trifluridine | Small molecule | 20 mg | Oral |